Stony Brook, NYNCT06149286Now EnrollingIRB Ready

Non-Hodgkin Lymphoma Clinical Trial in Stony Brook, NY

Access cutting-edge non-hodgkin lymphoma treatment through this phase 3 clinical trial at a research site in Stony Brook. Study-provided care at no cost to qualified participants.

Sponsored by Regeneron Pharmaceuticals

Quick Self-Assessment

See if you qualify for this Stony Brook location

Preparing your pre-screening questions…

Expert Care in Stony Brook

Access non-hodgkin lymphoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related non-hodgkin lymphoma treatment provided free

Apply for This Stony Brook Location

Check if you qualify for this non-hodgkin lymphoma clinical trial in Stony Brook, NY

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Stony Brook

    Convenient for NY residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Stony Brook site if eligible
  4. 4Begin participation

About This Non-Hodgkin Lymphoma Study in Stony Brook

This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called "relapsed"), or did not respond to treatment (called "refractory"). FL and MZL are subtypes of Non-Hodgkin 's lymphoma (NHL). This study will be made up of two parts (Part 1 not randomized, Part

Sponsor: Regeneron Pharmaceuticals

Who Can Participate

Inclusion Criteria

Local histologic confirmation of FL grade 1-3a or MZL (nodal, splenic, or extra nodal MZL) as assessed by the investigator, as described in the protocol.
Must have refractory disease or relapsed after at least 1 prior line (with a duration of at least 2 cycles) of systemic chemo-immunotherapy or immunotherapy. Prior systemic therapy should have included at least one anti-Cluster of Differentiation 20 (CD20) monoclonal antibody, and participant should meet indication for treatment, as described in the protocol.
Have measurable disease on cross sectional imaging documented by diagnostic Computed Tomography \[CT\], or Magnetic Resonance Imaging \[MRI\] imaging, as described in the protocol.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
Adequate hematologic and organ function, as described in the protocol.
All study participants must:
Have an understanding that lenalidomide could have a potential teratogenic risk.
Agree to abstain from donating blood while taking study drug therapy and for 28 days after discontinuation of lenalidomide.
Agree not to share study medication with another person.
Agree to be counseled about pregnancy precautions and risk of fetal exposure associated with lenalidomide. Key

Exclusion Criteria

Primary Central Nervous System (CNS) lymphoma or known involvement (either current or prior history of CNS involvement) by non-primary CNS NHL, as described in the protocol.
Participants with current or past histological evidence of high-grade or diffuse large B-cell lymphoma, or any histology other than FL grade 1-3a or MZL.
History of or current relevant CNS pathology, as described in the protocol.
A malignancy other than NHL (inclusion diagnosis) unless the participant is adequately and definitively treated and is cancer free for at least 3 years, with the exception of localized prostate cancer treated with hormone therapy or local radiotherapy (ie, pellets), cervical carcinoma in situ, breast cancer in situ, or nonmelanoma skin cancer that was definitively treated.
Any other significant active disease or medical condition that could interfere with the conduct of the study or put the participant at significant risk, as described in the protocol.
Allergy/hypersensitivity to study drugs or excipients. as described in the protocol.
Active infection as defined in the protocol. Note: Other protocol-defined Inclusion/Exclusion criteria apply

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Stony Brook?

Yes, this clinical trial (NCT06149286) has an active research site in Stony Brook, NY that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Non-Hodgkin Lymphoma Treatment Options in Stony Brook, NY

If you're searching for non-hodgkin lymphoma treatment options in Stony Brook, NY, this clinical trial (NCT06149286) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Stony Brook research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced non-hodgkin lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all non-hodgkin lymphoma clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Stony Brook, NY

See all lymphoma clinical trials recruiting in Stony Brook — not just this study.

Browse Lymphoma Trials in Stony Brook →

Browse More Trials by Condition

Lymphoma TrialsPulmonary Hypertension TrialsAll Conditions →

Ready to Join in Stony Brook?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Stony Brook, NY